ANTICANCER AGENTS CONTAINING EP1 ANTAGONISTS AS THE ACTIVE INGREDIENT

摘要

Preventives and/or remedies for cancer which contain EP1 antagonists as the active ingredient. Because of showing effects of inhibiting the formation of intestinal polyps and adenomas and inhibiting breast cancer, EP1 antagonists typified by 6-[(2S,3S)-3-(4-chloro-2-methylphenylsulfonylaminomethyl)-bicyclo[2.2.2]octan-2-yl]-5Z-hexenoic acid and 4-[2-[N-isobutyl-N-(2-furylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]cinnamic acid are useful in treating and/or preventing cancer.